skip to content

Trading statements

Skyepharma trading in line with views for FY

26 November 2015 07:37

Skyepharma said overall trading to date has continued to perform in line with directors' FY expectations. In addition, the group has benefited from higher cash receipts and, as a result, year-end cash is seen to be ahead of directors' previous expectations.

CEO Peter Grant commented:

"We remain on track to deliver substantial growth in revenues in 2015, with continued contributions from flutiform, Pacira's EXPAREL and the GSK Ellipta-range products.

"This strong performance underpins our ability to invest in building the pipeline for additional future growth as well as meeting anticipated future demand for flutiform.

"Today we have announced our plans to build on the success of flutiform by developing SKP-2076, a new ICS/LABA/LAMA triple combination product for the treatment of asthma. We believe SKP-2076 has the potential for relatively quick progress through clinical trials in Europe, putting Skyepharma in a position to benefit from the anticipated new market for fixed-combination triple therapies for asthma.

"SKP-2075 also has the potential for relatively quick development in Europe with our plan to generate dose-ranging data as part of our Phase II programme.

"With SKP-2075 in COPD/smoking asthma and SKP-2076 in asthma, additional potential indications and markets for flutiform and novel oral delivery technologies in development, we have a promising pipeline which we believe can deliver significant additional long-term growth."

Story provided by

Related Company: SKP

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.